Teclistamab shows promising results in frontline multiple myeloma treatment, achieving high MRD negativity rates, but safety concerns remain.
Marc Raab, MD
Advertisement
Articles by Marc Raab, MD
Advertisement
Latest Updated Articles
IMS 2025: Improving Outcomes With Bispecifics in Multiple MyelomaPublished: September 19th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Current Pneumococcal Vaccination Recommendations: A Clinical Update
2
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
3
Semaglutide Reduces Time in Spent in Hospital, Admission Rates in Patients With Overweight or Obesity
4
From the Pharmacy Counter to the Kitchen Cabinet: Helping Patients Choose Quality Supplements
5